TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
European Testing Week 14-21 May 2021
In times of COVID-19, European Testing Week aims to increase integrated testing efforts & promote awareness on the benefits of hepatitis and HIV testing! This Spring European Testing Week 2021 and with COVID-19, we won’t be going back to “testing as usual”. Find...
TherVacB website now available in four languages
Translations of the revised TherVacB website are now available in four languages! To make info about the TherVacB vaccination study and the European HBV Registry more accessible to a Europen audience, we have partnered with researchers at study centres to produce this...
European Testing Week 15-22 May 2020
European Testing Week 2020 aims to increase testing efforts & promote awareness on the benefits of hepatitis/HIV testing! More details here.
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
';
#ICYMI. In this📥slideset, expert faculty members summarize key viral #hepatitis studies from #ILC2021, including new data on treatment of #HDV, treatment of #HBV & #HCV in children, linking patients to care & new molecules being investigated for HBV cure➡️https://bit.ly/3hGa9RA
Looking for #WorldHepatitisDay materials? Let the world know that Hepatitis Can’t Wait by sharing @Hep_Alliance’s campaign resources on your organization’s platforms.
Access resources here:
https://bit.ly/3k86cH1
Interested in deciphering the #HBV life cycle ? Feel free to browse our last publication focused on #cccDNA and #HBc. 🦠 Thanks to the @HepvirTeam for allowing me to work on this project. https://twitter.com/hepvirteam/status/1415987548988510215
Our latest manuscript published by @JHEP_Reports is available on line! https://www.sciencedirect.com/science/article/pii/S2589555921001063
Thanks to @agenceANRS @inserm for funding our research! Congratulations to our team members including @salvetti_anna @David_Durantel @julie_lucifora @FlorentinPastor and the @EvirTeam!
Download our 'Hepatitis Can't Wait' campaign materials today and join this year's #WorldHepatitisDay campaign.
Materials are available to download in a range of languages!
https://www.worldhepatitisday.org/campaign-materials/
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.